Cooper Pharma and BioQ Pharma Enter into Strategic Partnership for Ropivacaine ReadyfusOR in Morocco
Sep 05, 2017
Casablanca, Morocco and San Francisco, CA, Sep. 5, 2017:
Cooper Pharma (“Cooper”) and BioQ Pharma Incorporated (“BioQ”), both specialty pharmaceutical companies, today announced a strategic partnership agreement to commercialize Ropivacaine ReadyfusOR in Morocco for the treatment of post-surgical pain in adults.
Ropivacaine ReadyfusOR, an opioid sparing post-surgical pain management therapy, is a disposable, ready-to-use, single use infusion product, which is pre-filled at the manufacturer with 0.2% Ropivacaine, a non-narcotic local anesthetic. It is a self-contained drug and administration system for delivery at the point of care, activated by a single touch. The Ropivacaine ReadyfusOR contains a unit-dose of the sterile drug and is hermetically sealed until time of use.
“We are pleased to add Cooper to our growing list of distinguished commercial partners,” said Josh Kriesel, President and CEO of BioQ Pharma. “BioQ believes that the Moroccan market is well positioned for Ropivacaine ReadyfusOR’s opioid sparing value proposition.”
Ayman Cheikh Lahlou, CEO of Cooper, commented, “We are pleased to have the opportunity to partner with BioQ to offer this innovative post-surgical pain management option and its benefits to patients and providers in Morocco. Ropivacaine ReadyfusOR’s intended benefits include: reducing manual dosing errors; eliminating the need for manual pharmaceutical compounding; reducing the use of opiates and duration of patient hospital stay, while at the same time, facilitating and speeding patient ambulation.”
About Cooper Pharma
Since 1933, Cooper Pharma, a Moroccan pharmaceutical company, assists healthcare professionals with a mission: Make medicines more available for all type of patients. Cooper Pharma is today a leading player in the pharmaceutical industry in the A&ME area (Middle East & Africa), with its wide range of branded generics and a range of licensed drugs in partnership with twenty multinationals covering more than 300 presentations in major therapeutic areas. Finally, Cooper Pharma started its export business nearly 20 years ago, starting first with the Maghreb and the countries of West Africa and Europe, and more recently East Africa. Cooper Pharma is currently present in thirty countries for exports with eight manufacturing plants in operations and two under construction in Africa and Middle East. "Because your health is our priority" is our motto and the core of our priorities
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, Galen Limited, Cooper Pharma, STADA Australia, Pharma Mart, and West Pharmaceutical Services.
BioQ Contact Information:
Josh Kriesel
BioQ Pharma
President and CEO
+1-415-336-6496
Ron Pauli
BioQ Pharma
Chief Financial Officer
+1-415-889-7707
Walter Cleymans
BioQ Pharma
Chief Commercial Officer
+32 474 (053) 253
Media:
Stephanie Carrington
Integrated Corporate Relations, Inc (ICR)
+1-646-277-1282
Cooper Contact Information:
Ayman Cheikh Lahlou
Cooper Pharma
CEO
+212522453200